Zentalis Pharmaceuticals, Inc. ZNTL
At closeNov 10, 2026, 5:24 PM EST
After hours · Nov 10, 5:24 PM ET
- YTD
- +33.33%
- 1 year
- +36.36%
- Market cap
- 176.62M
- Revenue (ttm)
- 40.56M
- EPS (ttm)
- -2.05
- Shares out
- 71.27M
- Forward P/E
- -0.89
- YTD return
- +33.33%
- 1-year return
- +36.36%
- Volume
- 2.56M
- Avg volume
- 1.25M
- Open
- 1.94
- Previous close
- 1.74
- Day's range
- 1.78 – 1.98
- 52-week range
- 1.25 – 6.95
- Beta
- 1.74
- Analysts
- Buy
- Price target
- 9.50 (+427.8%)
- Earnings date
- Aug 9, 2024
5D -0.05 (-2.66%)
Key statistics
- Enterprise value
- -134.19M
- PEG ratio
- 0.00
- Price / sales
- 5.59
- Price / book
- 0.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -81.91M
- Total cash
- 391.25M
- Total debt
- 43.27M
- Return on equity
- -42.89%
- Short % of float
- 13.19%
- 50-day average
- 3.31
- 200-day average
- 6.71
Analyst view
Consensus: buy
- Target (low)
- 4.00
- Target (mean)
- 9.50
- Target (high)
- 20.00
- Strong buy1
- Buy4
- Hold6
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -0.78181.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.92 | -0.56 | +0.36 | +39.13% |
| Aug 9, 2024 | Jun 1, 2024 | -0.83 | -1.24 | -0.41 | -49.40% |
| Aug 9, 2024 | Jun 1, 2024 | -0.83 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.85 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.85 | 0.14 | +0.99 | +116.47% |
| Feb 27, 2024 | Dec 1, 2023 | -0.92 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Guggenheim | main | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 16, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Aug 12, 2024 | Wedbush | up | Underperform | Neutral |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 20, 2024 | UBS | down | Buy | Neutral |
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- zentalis.com
News
Wedbush Upgrades Zentalis Pharmaceuticals to Outperform, Raises Price Target to $6 
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences 
Zentalis Pharmaceuticals Presents Data From Its Interim Analysis Of DENALI Part 1b Trial At ESMO Congress 2026 - HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target
Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8 
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales - William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on ZNTL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| EPPERLY MELISSA B | Chief Financial Officer | Sale | Feb 11, 2024 | 451,449 |
| GALLAGHER CAM S | President | Sale | May 30, 2024 | 633,680 |
| HAUSMAN DIANA | Officer | Sale | May 8, 2024 | 373,876 |
| JOHNSON DAVID MICHAEL | Director | Stock Award(Grant) | Jun 20, 2024 | 192,818 |
| KARIUKI ENOCH | Director | Stock Award(Grant) | Jun 20, 2024 | 79,762 |
| LACKNER MARK | Officer | Sale | Feb 1, 2024 | 195,728 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Matrix Capital Management | 19.59% | 13,959,973 | 44.39M | Sep 29, 2024 |
| Eventide Asset Management LLC | 11.99% | 8,547,896 | 27.18M | Sep 29, 2024 |
| FMR, LLC | 7.12% | 5,075,837 | 16.14M | Sep 29, 2024 |
| Blackrock Inc. | 6.68% | 4,761,173 | 15.14M | Sep 29, 2024 |
| Vanguard Group Inc | 6.47% | 4,612,707 | 14.67M | Sep 29, 2024 |
| Decheng Capital LLC | 4.36% | 3,108,095 | 9.88M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 6.94% | 4,948,595 | 15.74M | Sep 29, 2024 |
| Mutual Fund Ser Tr-Eventide Gilead Fund | 5.03% | 3,584,309 | 11.40M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.66% | 1,893,087 | 6.02M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.01% | 1,432,675 | 4.56M | Oct 30, 2024 |
| Primecap Odyssey Aggressive Growth Fund | 1.55% | 1,104,410 | 3.51M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.26% | 896,551 | 2.85M | Sep 29, 2024 |